Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mito-TEMPO is a mitochondria-targeted antioxidant small molecule designed to accumulate within mitochondria and scavenge reactive oxygen species (ROS), particularly superoxide and alkyl radicals. It consists of the piperidine nitroxide TEMPO moiety conjugated to a triphenylphosphonium cation for mitochondrial targeting. By reducing mitochondrial oxidative stress, mito-TEMPO protects against cellular damage in various models of disease including acetaminophen-induced hepatotoxicity, N-nitrosodiethylamine-induced hepatocarcinogenesis in mice, renal fibrosis, ischemic brain injury, and noise-induced hearing loss. Its mechanism involves mimicking superoxide dismutase activity within mitochondria and preventing ROS-mediated damage to mitochondrial components[1][2][3][5][7]. It is used primarily as a research tool in both in vitro and in vivo studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mito-TEMPO.